Tyme Technologies (TYME) Granted U.S. Patent Claims Covering Use of TYME-19 to Treat COVID-19 Infections
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/15/2026
- Wall St futures edge up with earnings in focus; PayPal jumps
- Oil prices rise 1% as hostilities worsen in the Middle East
- Dollar on back foot as softer US inflation dims Fed hike bets
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- Fed’s Warsh says central bank won’t tolerate high inflation
- IBM misses Q2 targets as mainframe and software sales disappoint
- Verizon planning new round of layoffs this week - Barron’s
- Kosovo bans Serb minister over ethnic cleansing remarks
- Lucid Group shares quickly cut in half on report of potential bankruptcy
- S&P 500 and Nasdaq end higher on cool inflation data, solid bank earnings
Tyme Technologies (TYME) Prices 40M Share Registered Direct Common Offering at $2.50/Sh
February 4, 2021 6:00 AM ESTTyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTsTM), today announced that it has entered into definitive agreements with several healthcare-focused institutional and other institutional investors for the sale of an aggregate of 40,000,000 shares of its common stock at a purchase price of $2.50 per share in a registered direct offering priced at-the-market under... More
Tyme Technologies (TYME) Climbs 110%
February 3, 2021 8:17 AM ESTTyme Technologies (NASDAQ: TYME) Climbs 110%
Earlier Tyme Technologies (TYME) Granted U.S. Patent Claims Covering Use of TYME-19 to Treat COVID-19 Infections... More